Modest Predictive Accuracy for CHA2DS2-VASc in Heart Failure

This article originally appeared here.
Share this content:
Modest Predictive Accuracy for CHA<sub>2</sub>DS<sub>2</sub>-VASc in Heart Failure
Modest Predictive Accuracy for CHA2DS2-VASc in Heart Failure

MONDAY, Aug. 31 2015 (HealthDay News) -- The predictive accuracy of the CHA2DS2-VASc score for ischemic stroke, thromboembolism, and death in patients with heart failure with and without concomitant atrial fibrillation (AF) is modest, according to findings published online Aug. 30 in the Journal of the American Medical Association to coincide with the annual European Society of Cardiology Congress, held from Aug. 29 to Sept. 2 in London.

Line Melgaard, from Aalborg University in Denmark, and colleagues examined whether CHA2DS2-VASc predicts ischemic stroke, thromboembolism, and death among patients with heart failure, with and without AF. Data were included for 42,987 patients not receiving anticoagulation who were diagnosed with incidence heart failure during 2000 to 2012 (21.9 percent had concomitant AF).

The researchers found that the risks of ischemic stroke, thromboembolism, and death were 3.1, 9.9, and 21.8 percent, respectively, with risks increasing with CHA2DS2-VASc scores, for those with and without concomitant AF. In this population, C-statistics and negative predictive values indicated that the CHA2DS2-VASc score performed modestly for those with and without AF (for ischemic stroke: one-year C-statistic, 0.67 and 0.64, respectively; one-year negative predictive values, 92 and 91 percent, respectively).

"Predictive accuracy was modest, and the clinical utility of the CHA2DS2-VASc score in patients with heart failure remains to be determined," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »